慢性粒细胞白血病十年进展 - Suppr

Suppr

超能文献

10 years of progress in chronic myelogenous leukemia.

作者信息

Jabbour Elias, Mathisen Michael S, O'Brien Susan

机构信息

The University of Texas MD Anderson Cancer Center Houston, Texas, USA.

出版信息

J Natl Compr Canc Netw. 2012 Sep;10(9):1049-53. doi: 10.6004/jnccn.2012.0110.

DOI:10.6004/jnccn.2012.0110

PMID:22956803

Abstract

摘要

相似文献

10 years of progress in chronic myelogenous leukemia.

J Natl Compr Canc Netw. 2012 Sep;10(9):1049-53. doi: 10.6004/jnccn.2012.0110.

As leukemia options grow, drugs jockey to be first-line therapies.

Nat Med. 2013 Jan;19(1):7. doi: 10.1038/nm0113-7.

BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.

N Engl J Med. 2007 Jul 19;357(3):258-65. doi: 10.1056/NEJMct071828.

Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].

Clin Adv Hematol Oncol. 2008 Nov;6(11):797-9.

Circumventing resistance to kinase-inhibitor therapy.

N Engl J Med. 2006 Jun 15;354(24):2594-6. doi: 10.1056/NEJMe068073.

First-line therapy for CML: nilotinib comes of age.

Lancet Oncol. 2011 Sep;12(9):826-7. doi: 10.1016/S1470-2045(11)70228-5. Epub 2011 Aug 17.

[New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].

Zhonghua Zhong Liu Za Zhi. 2006 Aug;28(8):561-3.

[State of the art in the treatment of chronic leukemias].

Rinsho Ketsueki. 2006 Apr;47(4):278-86.

Loss of response to imatinib: mechanisms and management.

Hematology Am Soc Hematol Educ Program. 2005:183-7. doi: 10.1182/asheducation-2005.1.183.

Ever-advancing chronic myeloid leukemia treatment.

Int J Clin Oncol. 2014 Feb;19(1):3-9. doi: 10.1007/s10147-013-0641-7. Epub 2013 Nov 22.

引用本文的文献

Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.

Autophagy. 2015;11(2):355-72. doi: 10.4161/15548627.2014.994368.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

10 years of progress in chronic myelogenous leukemia.

作者信息

Jabbour Elias, Mathisen Michael S, O'Brien Susan

机构信息

The University of Texas MD Anderson Cancer Center Houston, Texas, USA.

出版信息

J Natl Compr Canc Netw. 2012 Sep;10(9):1049-53. doi: 10.6004/jnccn.2012.0110.

DOI:10.6004/jnccn.2012.0110

PMID:22956803

Abstract

摘要

相似文献

10 years of progress in chronic myelogenous leukemia.

J Natl Compr Canc Netw. 2012 Sep;10(9):1049-53. doi: 10.6004/jnccn.2012.0110.

As leukemia options grow, drugs jockey to be first-line therapies.

Nat Med. 2013 Jan;19(1):7. doi: 10.1038/nm0113-7.

BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.

N Engl J Med. 2007 Jul 19;357(3):258-65. doi: 10.1056/NEJMct071828.

Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].

Clin Adv Hematol Oncol. 2008 Nov;6(11):797-9.

Circumventing resistance to kinase-inhibitor therapy.

N Engl J Med. 2006 Jun 15;354(24):2594-6. doi: 10.1056/NEJMe068073.

First-line therapy for CML: nilotinib comes of age.

Lancet Oncol. 2011 Sep;12(9):826-7. doi: 10.1016/S1470-2045(11)70228-5. Epub 2011 Aug 17.

[New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].

Zhonghua Zhong Liu Za Zhi. 2006 Aug;28(8):561-3.

[State of the art in the treatment of chronic leukemias].

Rinsho Ketsueki. 2006 Apr;47(4):278-86.

Loss of response to imatinib: mechanisms and management.

Hematology Am Soc Hematol Educ Program. 2005:183-7. doi: 10.1182/asheducation-2005.1.183.

Ever-advancing chronic myeloid leukemia treatment.

Int J Clin Oncol. 2014 Feb;19(1):3-9. doi: 10.1007/s10147-013-0641-7. Epub 2013 Nov 22.

引用本文的文献

Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.

Autophagy. 2015;11(2):355-72. doi: 10.4161/15548627.2014.994368.